Valeant Pharmaceuticals Intl Inc

Xavier Trudeau
Juillet 18, 2017

According to Zacks, "Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services". The company has 2.01 value in price to sale ratio while price to book ratio was recorded as 47.04. "Shares have underperformed the broader industry".

05/09/2017 - Valeant Pharmaceuticals International, Inc. had its "neutral" rating reiterated by analysts at BTIG Research. Scotiabank reduced their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a "sector perform" rating for the company in a research report on Wednesday, April 26th. Jefferies Group LLC set a $18.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a buy rating in a research report on Saturday, May 6th. Finally, Wells Fargo & Company reiterated a "sell" rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 27th. Community Tru Inv holds 0.04% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 25,095 shares. (VRX) were valued at $17.24 and moved -0.29% as of a recent closing trade. Based on an average daily volume of 19,186,434 shares, the days-to-cover ratio is presently 2.6 days. The stock attained the volume of 12.44 million shares contrast to its average daily volume of 21.49 million shares. Not so with Valeant Pharmaceuticals International, Inc. Hap Trading Llc who had been investing in Valeant Pharmaceuticals Intl (Put) for a number of months, seems to be less bullish one the $6.02 billion market cap company.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.93. The company had revenue of $2.11 billion for the quarter, compared to analysts' expectations of $2.17 billion. Columbus Hill Mngmt Limited Partnership holds 1.12% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 685,000 shares. During the same quarter in the previous year, the business posted ($1.08) earnings per share. The consensus recommendation, according to Zacks Investment research, is 3. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & global trademark and copyright legislation. The original version of this piece can be viewed at

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 20,000 shares of the business's stock in a transaction dated Thursday, May 11th. The shares were bought at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the purchase, the director now owns 70,572 shares in the company, valued at $980,950.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. (VRX) have 342.74 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRX. Private Capital Management Inc. purchased a new stake in shares of Valeant Pharmaceuticals Intl during the first quarter worth about $154,000. Moving out to look at the previous month volatility move, the stock is at 4.95%. Searle & CO. acquired a new position in Valeant Pharmaceuticals International during the fourth quarter worth $972,000. About shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since July 14, 2016 and is downtrending. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company's stock worth $30,631,000 after buying an additional 903,256 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Valeant Pharmaceuticals International by 9.8% in the second quarter. GSA Capital Partners LLP now owns 35,415 shares of the specialty pharmaceutical company's stock worth $514,000 after buying an additional 8,718 shares during the period. ValueAct Holdings L.P. increased its stake in shares of Valeant Pharmaceuticals International by 20.0% in the first quarter. There is no concrete way to calculate a price target.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

D'autres rapports CampDesrEcrues

Discuter de cet article